Biopharma Deals and Funding Trends through Q1 2023 from DealForma

Biopharma Deals and Funding Trends – Review of 2022 and Updates through Q1 2023

by Chris DokomajilarApr 3, 2023Analysis, Funding, M&A, Partnership Deals

Deal Flow in 2022 Returned to pre-2019 Levels

Chart showing number of healthcare and life sciences deals by deal type

Lower Deal Dollars Across All Healthcare and Life Sciences

Licensing Terms are Shifting to More in Milestones

Large Cap Biopharma In-Licensing and Buying in 2022

Big Pharma Pays Well for Phase II as POC Returns

Large Cap Biopharma Therapy Areas and Modalities in Focus

R&D Partnership Activity in Oncology

R&D Partnership Activity in Neurology

R&D Partnership Upfronts in the Top Modalities

Healthcare and Life Sciences Venture Returned to pre-2020

All Company Stages Saw Lower Venture Activity

Biopharma M&A Volume Increased in Q1

20,378

Licensing Deals

17,730

Funding Rounds

4,034

M&A

31,012

Company Profiles

5,478

Other Deals

26,505

Drug Sales Figures

All of this by stage, disease indication, modality, target...

Schedule Your Demo

More Research by DealForma

May 2023 Top Biopharma Deal: Cellular Biomedicine development and commercialization deal with Janssen for C-CAR039 and C-CAR066

Jun 1, 2023 | Deal of the Month

Introducing: DealForma plus Tableau

May 30, 2023 | Product Support and Tips, Updates

We are excited to introduce DealForma's new Tableau dashboard integration. High quality data on biopharma deals and funding meets interactive charts and visuals. DealForma customers will have exclusive access to the DealForma chart dashboards built on Tableau right...

Venture & IPO – Medtech – Q1 2023

May 23, 2023 | Analysis, Funding

The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...